News & Blog

Press Release and Community Statement: Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia

Meet the Community: Mark Kuchmas

Meet the Community: Luciana Grasiele Nogueira

Webinar Recording: Biogen May 2025 Update

Webinar Recording: Lexeo Therapeutics May 2025 Update

Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2

Gehr Family shares their FA journey, how they raise awareness of Friedreich’s ataxia, and the upcoming Cure FA Soirée with local media outlets

Meet the Community: Alyssa Hammers

Meet the Community: Christi Wilson

Meet the Community: Talia Cassel

Participating in Research: Marc and Maggie Likins

Community Statement: Biogen announces BRAVE Phase 3 Pediatric Study of Omaveloxolone